SLDB Solid Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SLDB

Price (delayed)

$10.1

Market cap

$381.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.83

Enterprise value

$331.76M

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by ...

Highlights
The debt fell by 8% YoY and by 2.1% QoQ
The EPS has surged by 52% year-on-year but it has declined by 7% since the previous quarter
SLDB's gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://solidbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SLDB
Market
Shares outstanding
37.76M
Market cap
$381.34M
Enterprise value
$331.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$96.02M
EBITDA
-$93.43M
Free cash flow
-$95.7M
Per share
EPS
-$4.83
Free cash flow per share
-$4.81
Book value per share
$6.27
Revenue per share
$0
TBVPS
$8.3
Balance sheet
Total assets
$164.94M
Total liabilities
$38.46M
Debt
$26.27M
Equity
$126.48M
Working capital
$115.22M
Liquidity
Debt to equity
0.21
Current ratio
8.94
Quick ratio
8.64
Net debt/EBITDA
0.53
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49%
Return on equity
-62.1%
Return on invested capital
-87.5%
Return on capital employed
-63.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SLDB stock price

How has the Solid Biosciences stock price performed over time
Intraday
-1.27%
1 week
12.47%
1 month
-19.33%
1 year
90.57%
YTD
64.5%
QTD
-24.17%

Financial performance

How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$104.25M
Net income
-$96.02M
Gross margin
N/A
Net margin
N/A
SLDB's gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
The net income fell by 12% YoY and by 6% QoQ
The operating income has grown by 11% since the previous quarter and by 2.1% year-on-year

Growth

What is Solid Biosciences's growth rate over time

Valuation

What is Solid Biosciences stock price valuation
P/E
N/A
P/B
1.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 52% year-on-year but it has declined by 7% since the previous quarter
The price to book (P/B) is 168% more than the last 4 quarters average of 0.6 but 5% less than the 5-year quarterly average of 1.7
The equity has declined by 40% year-on-year and by 12% since the previous quarter
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Solid Biosciences business performance
Solid Biosciences's return on equity has decreased by 27% YoY and by 20% QoQ
The return on assets has declined by 23% year-on-year and by 19% since the previous quarter
The ROIC is down by 18% YoY and by 8% QoQ

Dividends

What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLDB.

Financial health

How did Solid Biosciences financials performed over time
The total assets has contracted by 37% YoY and by 11% from the previous quarter
The total liabilities has contracted by 21% YoY and by 4.7% from the previous quarter
The debt is 79% lower than the equity
The debt to equity has soared by 62% YoY and by 11% from the previous quarter
The equity has declined by 40% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.